The Canadian Cancer Survivor Network was pleased to offer another webinar on precision medicine and diagnostic services, welcoming oncology and pathology centre expertise along with policy experts to share their perspectives. The Survivor community can learn more about the state of the art in new tests available in cancer centres, which pinpoint specific types of tumours that will respond best to treatments.
In addition, the Canadian Agency for Drugs and Technologies in Health is currently consulting with stakeholders on a framework for evaluating the clinical and economic aspects of diagnostics related to treatments. The Canadian Association of Provincial Cancer Agencies is undertaking a framework for determining the affordability of new oncology therapies.
The webinar was co-hosted by 3Sixty Public Affairs’ Bill Dempster and Rachael Manion, who will introduce the topic, along with a special guest, Dr. Tracy Stockley, an expert in the development and use of genomic tests for molecular diagnostics, application of new technologies such as Next-Generation Sequencing to clinical care and high-complexity clinical laboratory testing.
Bill Dempster, CEO of 3Sixty Public Affairs, is a seasoned health and pharmaceutical policy expert who works with a range of clients to navigate complex political, policy, regulatory and reimbursement challenges.
Rachael Manion, Senior Associate at 3Sixty Public Affairs, draws on her legal background and government policy experience to provide strategic advice to clients.
Dr. Tracy Stockley, Associate Director of Genome Diagnostics at Princess Margaret Cancer Centre, is a clinical scientist with more than twenty years’ experience in genetic testing and precision medicine for oncology.
To view the slides, please click here.